经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展
Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma
张岩基 1王汇源 1李浩 2段旭华2
作者信息
- 1. 450052 河南郑州 郑州大学临床医学院
- 2. 郑州大学第一附属医院介入放射科
- 折叠
摘要
原发性肝癌是全球常见恶性肿瘤,在我国是第4位常见恶性肿瘤和第2位肿瘤致死病因.我国肝细胞癌(HCC)患者确诊时大多为中晚期,已无法接受根治性治疗.目前以经导管动脉化疗栓塞术(TACE)为主的局部治疗联合全身治疗已成为不可切除HCC主流治疗方案,而肝动脉灌注化疗(HAIC)作为一种新选择受到广泛关注.该文综述了 TACE联合HAIC治疗HCC研究新进展,得出结论为TACE联合HAIC对不可切除的BCLC分期C期、巨块型HCC及门静脉受侵患者的疗效优于TACE,但对BCLC分期A/B期患者的疗效与TACE无明显差异.希望能为临床HCC患者治疗提供有效建议,并为进一步规范TACE及后期HAIC,设计相关临床研究提供依据.
Abstract
Primary hepatocellular carcinoma(HCC)is a common malignant tumor in the world,and in China it is the fourth most common malignant tumor and the second cause of cancer mortality.In China,most HCC patients are already in the advanced stage when the clinical diagnosis of HCC is confirmed,and it is impossible to adopt a radical treatment for the patient.At present,transarterial chemoembolization(TACE)has become the mainstream therapeutic option for unresectable HCC,and hepatic arterial perfusion chemotherapy(HAIC),as a new therapeutic option,has attracted extensive attention.This article reviews the research progress in TACE combined with HAIC for the treatment of HCC,and obtains the following conclusions:TACE combined with HAIC has better efficacy than TACE along in patients with unresectable HCC of BCLC stage C,massive HCC,and portal venous invasion,but there is no significant difference in the therapeutic efficacy between TACE combined with HAIC and TACE alone for patients with HCC of BCLC stage A/B.It is expected that this review will provide effective recommendations for treating HCC patients in clinical practice,further standardize TACE treatment and later-stage HAIC treatment,and provide the basis for the design of relevant clinical studies.
关键词
肝细胞癌/经导管动脉化疗栓塞术/肝动脉灌注化疗Key words
hepatocellular carcinoma/transcatheter arterial chemoembolization/hepatic arterial perfusion chemotherapy引用本文复制引用
基金项目
河南省医学科技攻关省部共建重大项目(SBGJ202102100)
国家自然科学基金(U2004119)
出版年
2024
NETL
NSTL
万方数据